ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab

Meral Uner; Bassam Alhasson; Jagdeep Obhrai; Serena M. Bagnasco

doi:10.1007/s00428-020-02882-w

ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab

Meral Uner, Bassam Alhasson, Jagdeep Obhrai, Serena M. Bagnasco

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer immunotherapy is rapidly changing the treatment paradigm in oncology, and immune checkpoint inhibitors (ICPIs) have been used successfully in a variety of cancer types. Specific side effects termed immune-related adverse events (irAEs) have now been described in various organ systems, including the kidney. Renal complications have rarely been reported compared with other irAEs and mostly consist of acute interstitial nephritis. Only rare cases of ICPI-related glomerulonephritis have been described. Herein, we report the case of an adult patient treated with pembrolizumab (anti-PD-1) for squamous cell carcinoma (SCC), who developed infectious enterocolitis, and ANCA-related with diffuse necrotizing crescentic glomerulonephritis, both conditions potentially linked to treatment with pembrolizumab.

Original language	English (US)
Pages (from-to)	801-804
Number of pages	4
Journal	Virchows Archiv
Volume	478
Issue number	4
DOIs	https://doi.org/10.1007/s00428-020-02882-w
State	Published - Apr 2021

Keywords

ANCA
Crescentic glomerulonephritis
Immune checkpoint inhibitor
Immune-related adverse events
PD-1
Pembrolizumab

ASJC Scopus subject areas

Molecular Biology
Pathology and Forensic Medicine
Cell Biology

Access to Document

10.1007/s00428-020-02882-w

Cite this

@article{a62dad3a628b4936b2bb9f55c1263f22,

title = "ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab",

abstract = "Cancer immunotherapy is rapidly changing the treatment paradigm in oncology, and immune checkpoint inhibitors (ICPIs) have been used successfully in a variety of cancer types. Specific side effects termed immune-related adverse events (irAEs) have now been described in various organ systems, including the kidney. Renal complications have rarely been reported compared with other irAEs and mostly consist of acute interstitial nephritis. Only rare cases of ICPI-related glomerulonephritis have been described. Herein, we report the case of an adult patient treated with pembrolizumab (anti-PD-1) for squamous cell carcinoma (SCC), who developed infectious enterocolitis, and ANCA-related with diffuse necrotizing crescentic glomerulonephritis, both conditions potentially linked to treatment with pembrolizumab.",

keywords = "ANCA, Crescentic glomerulonephritis, Immune checkpoint inhibitor, Immune-related adverse events, PD-1, Pembrolizumab",

author = "Meral Uner and Bassam Alhasson and Jagdeep Obhrai and Bagnasco, {Serena M.}",

note = "Funding Information: Dr. Meral Uner was partially supported by the Hacettepe University Scientific Research Projects Coordination Unit (Project: TUI-2019-18392) during her fellowship. Publisher Copyright: {\textcopyright} 2020, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2021",

month = apr,

doi = "10.1007/s00428-020-02882-w",

language = "English (US)",

volume = "478",

pages = "801--804",

journal = "Virchows Archiv",

issn = "0945-6317",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab

AU - Uner, Meral

AU - Alhasson, Bassam

AU - Obhrai, Jagdeep

AU - Bagnasco, Serena M.

N1 - Funding Information: Dr. Meral Uner was partially supported by the Hacettepe University Scientific Research Projects Coordination Unit (Project: TUI-2019-18392) during her fellowship. Publisher Copyright: © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2021/4

Y1 - 2021/4

N2 - Cancer immunotherapy is rapidly changing the treatment paradigm in oncology, and immune checkpoint inhibitors (ICPIs) have been used successfully in a variety of cancer types. Specific side effects termed immune-related adverse events (irAEs) have now been described in various organ systems, including the kidney. Renal complications have rarely been reported compared with other irAEs and mostly consist of acute interstitial nephritis. Only rare cases of ICPI-related glomerulonephritis have been described. Herein, we report the case of an adult patient treated with pembrolizumab (anti-PD-1) for squamous cell carcinoma (SCC), who developed infectious enterocolitis, and ANCA-related with diffuse necrotizing crescentic glomerulonephritis, both conditions potentially linked to treatment with pembrolizumab.

AB - Cancer immunotherapy is rapidly changing the treatment paradigm in oncology, and immune checkpoint inhibitors (ICPIs) have been used successfully in a variety of cancer types. Specific side effects termed immune-related adverse events (irAEs) have now been described in various organ systems, including the kidney. Renal complications have rarely been reported compared with other irAEs and mostly consist of acute interstitial nephritis. Only rare cases of ICPI-related glomerulonephritis have been described. Herein, we report the case of an adult patient treated with pembrolizumab (anti-PD-1) for squamous cell carcinoma (SCC), who developed infectious enterocolitis, and ANCA-related with diffuse necrotizing crescentic glomerulonephritis, both conditions potentially linked to treatment with pembrolizumab.

KW - ANCA

KW - Crescentic glomerulonephritis

KW - Immune checkpoint inhibitor

KW - Immune-related adverse events

KW - PD-1

KW - Pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85088261880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088261880&partnerID=8YFLogxK

U2 - 10.1007/s00428-020-02882-w

DO - 10.1007/s00428-020-02882-w

M3 - Article

C2 - 32691143

AN - SCOPUS:85088261880

SN - 0945-6317

VL - 478

SP - 801

EP - 804

JO - Virchows Archiv

JF - Virchows Archiv

IS - 4

ER -

ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this